PDF(Pubmed)
Abstract：
Studies examining the role of signal transducer and activator of transcription 5 (STAT5) in various cancers have produced controversial results. To address this controversy, we examined the prognostic role of STAT5a in cancer patients across multiple cancers. Transcription levels of STAT5a between tumors and normal tissues, obtained from public databases, were analyzed for statistical differences using Cox regression analysis with the outcome as overall survival and covariate of interest as high STAT5a expression. Meta-analysis was then conducted to summarize the hazard ratio estimate from the Cox regression analyses. We found that STAT5a was significantly under-expressed in breast, lung, and ovarian cancers, while STAT5a was significantly overexpressed in lymphoid neoplasm diffuse large B-cell lymphoma, glioblastoma, and glioma. High STAT5a expression was significantly associated with favorable survival in bladder cancer (lnHR = -0.8689 [-1.4087, -0.3292], P-value = 0.0016), breast cancer (lnHR = -0.7805 [-1.1394, -0.4215], P-value < 0.0001) and lung cancer (lnHR = -0.3255 [-0.6427, -0.0083], P-value = 0.0443). After adjusting for clinicopathological factors, high STAT5a expression remained significantly associated with favorable survival in breast cancer (lnHR = -0.6091 [-1.0810, -0.1372], P-value = 0.0114). These results suggest that higher STAT5a expression is associated with favorable overall survival in breast cancer, and therefore might have protective effects, and that STAT5a expression could be a potential prognostic biomarker, especially in breast cancer. However, the prognostic role of STAT5a is dependent on cancer type.
摘要：
研究信号转导和转录激活因子5（STAT5）在各种癌症中的作用产生了有争议的结果。为了解决这个争议，我们研究了STAT5a在多种癌症患者中的预后作用.肿瘤和正常组织之间STAT5a的转录水平，从公共数据库获得，使用Cox回归分析进行统计学差异分析，结果为总生存期，感兴趣的协变量为高STAT5a表达。然后进行Meta分析，总结Cox回归分析的风险比估计。我们发现STAT5a在乳腺中显著低表达,肺，卵巢癌，而STAT5a在淋巴样肿瘤弥漫性大B细胞淋巴瘤中显著过表达,胶质母细胞瘤,还有神经胶质瘤.STAT5a高表达与膀胱癌患者的良好生存率显著相关(lnHR=-0.8689[-1.4087;-0.3292],p值=0.0016)，乳腺癌（lnHR=-0.7805[-1.1394；-0.4215]，p值<0.0001）和肺癌（lnHR=-0.3255[-0.6427；-0.0083]，p值=0.0443)。在调整临床病理因素后，STAT5a高表达仍然与乳腺癌的有利生存率显着相关（lnHR=-0.6091[-1.0810;-0.1372]，p值=0.0114)。这些结果表明，在乳腺癌中，较高的STAT5a表达与良好的总体生存率相关。因此可能有保护作用，STAT5a表达可能是一个潜在的预后生物标志物，尤其是乳腺癌。然而,STAT5a的预后作用取决于癌症类型.
